Instacart downgraded as competition tightening grip on online grocery
Precigen, INC. NASDAQ:PGEN Chief Financial Officer Harry Thomasian Jr. reported purchasing shares of the company’s common stock in two transactions, with a total value of $40,015. The insider buying comes as the stock has shown remarkable strength, delivering a 282% return over the past year. According to InvestingPro data, analysts have set price targets between $8.00 and $8.50, suggesting significant upside potential from current levels.
According to a Form 4 filing with the Securities and Exchange Commission, on September 25, 2025, Thomasian acquired 8,284 shares of Precigen at a weighted average price of $3.62
Following these transactions, Thomasian directly owns 468,626 shares of Precigen, INC. The company maintains a healthy liquidity position with a current ratio of 2.71, indicating strong ability to meet short-term obligations. For deeper insights into Precigen’s financial health and growth prospects, including 12 additional exclusive ProTips, visit InvestingPro.
In other recent news, Precigen, Inc. has converted 79,000 shares of its 8.00% Series A Convertible Perpetual Preferred Stock into 54,937,411 common shares. This conversion was executed without the need for registration, in line with the company’s corporate structure. In addition to this corporate action, Precigen secured $100 million in non-dilutive financing through a credit facility agreement with Pharmakon Advisors, LP, which could potentially provide up to $125 million. The initial tranche of $100 million has already been funded, with an option for an additional $25 million available until March 31, 2027, under certain conditions.
Cantor Fitzgerald has reiterated its Overweight rating on Precigen, maintaining a positive outlook following these developments. Meanwhile, H.C. Wainwright continues to support the company with a Buy rating and an $8.50 price target, particularly after the FDA’s full approval of Papzimeos for treating recurrent respiratory papillomatosis. This approval, announced ahead of the expected PDUFA date, includes a wholesale acquisition cost of $460,000 for a full treatment cycle. These recent events underscore significant financial and regulatory milestones for Precigen.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.